Broach Lifecare Hospital Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039354,
    "name": "Broach Lifecare",
    "stock_name": "Broach Lifecare",
    "full_name": "Broach Lifecare Hospital Ltd",
    "name_url": "stocks-analysis/broach-lifecare",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "15.50",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "15.50",
    "mcapval": "9.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544231,
    "symbol": "",
    "ind_name": "Hospital",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE0SFZ01018",
    "curr_date": "Dec 03",
    "curr_time": "",
    "bse_nse_vol": 12000,
    "exc_status": "Active",
    "traded_date": "Dec 03, 2025",
    "traded_date_str": "2025 12 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/broach-lifecare-10039354-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Broach Lifecare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-broach-lifecare-3704362",
        "imagepath": "",
        "date": "2025-11-15 00:35:57",
        "description": "Answer:\nThe historical performance of Broach Lifecare shows a mixed trend in financial metrics from March 2024 to March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Broach Lifecare reported net sales of 3.18 Cr, an increase from 2.61 Cr in the previous year. Total operating income also rose to 3.18 Cr from 2.61 Cr, while total expenditure increased to 2.35 Cr from 1.58 Cr. Operating profit (PBDIT) decreased to 0.88 Cr from 1.03 Cr, leading to a decline in profit before tax to 0.72 Cr from 0.93 Cr. Consequently, profit after tax fell to 0.54 Cr from 0.70 Cr. The earnings per share (EPS) dropped to 0.89 from 1.57, reflecting a decrease in profitability. On the balance sheet, shareholder's funds grew to 9.36 Cr from 5.47 Cr, and total liabilities increased to 10.92 Cr from 5.72 Cr. The company reported a cash flow from financing activities of 4.00 Cr, consistent with the previous year, while cash fl..."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3678251",
        "imagepath": "",
        "date": "2025-11-07 08:14:28",
        "description": "As of 6 November 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 20.23, an EV to EBITDA of 11.78, and a ROCE of 6.90%. \n\nIn comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than that of Apollo Hospitals, which stands at 71.27, highlighting a substantial valuation gap. Additionally, while Broach Lifecare's PEG Ratio is at 0.00, indicating no growth expectations, other peers like Max Healthcare and Fortis Health are considered very expensive with PEG Ratios of 6.38 and 1.88, respectively. Despite a recent stock return of 3.75% over the past week, Broach Lifecare has underperformed the Sensex over the longer term, with a year-to-date decline of 16.67% compared to the Sensex's gain of 6.62%...."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3605688",
        "imagepath": "",
        "date": "2025-10-09 08:07:08",
        "description": "As of 8 October 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive. Based on the analysis, the company appears to be undervalued. Key ratios include a PE Ratio of 10.35, an EV to EBIT of 11.20, and a ROCE of 6.90%. \n\nIn comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than Apollo Hospitals at 70.05 and Max Healthcare at 92.31, both of which are categorized as very expensive. The PEG Ratio for Broach Lifecare stands at 0.00, indicating potential growth at a low price, further supporting the undervaluation thesis. Additionally, Broach Lifecare's recent stock performance has lagged behind the Sensex, with a year-to-date return of -21.06% compared to the Sensex's 4.65%, reinforcing the notion that the stock may be undervalued in the current market environment...."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3556537",
        "imagepath": "",
        "date": "2025-09-23 08:06:53",
        "description": "As of 22 September 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.84, an EV to EBITDA ratio of 12.69, and a Price to Book Value of 1.27. These ratios suggest that the company is trading at a reasonable valuation compared to its earnings and book value.\n\nIn comparison to its peers, Broach Lifecare's PE ratio is significantly lower than that of Max Healthcare, which is considered very expensive at a PE of 94.6, and also lower than Apollo Hospitals, which has a PE of 70.79 but is rated attractive. This positions Broach Lifecare favorably within the industry, especially given its lower PEG ratio of 0.00, indicating potential for growth at a reasonable price. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -9.72% compar..."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3550243",
        "imagepath": "",
        "date": "2025-09-22 08:08:08",
        "description": "As of 19 September 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive. The company is currently assessed as undervalued. Key ratios include a PE ratio of 10.93, an EV to EBITDA ratio of 11.78, and a Price to Book Value of 1.18, which indicate a favorable valuation compared to its peers.\n\nIn comparison to notable competitors, Apollo Hospitals has a significantly higher PE ratio of 71.29 and an EV to EBITDA of 36.650, while Max Healthcare is even more expensive with a PE of 93.83 and an EV to EBITDA of 58.130. This stark contrast highlights Broach Lifecare's relative undervaluation in the market. Additionally, the company's recent stock performance has lagged behind the Sensex, with a one-year return of -25.38% compared to the Sensex's -0.67%, reinforcing the notion that it may be undervalued...."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3549634",
        "imagepath": "",
        "date": "2025-09-21 08:07:09",
        "description": "As of 19 September 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently undervalued, with a PE ratio of 10.93, an EV to EBITDA ratio of 11.78, and a Price to Book Value of 1.18. These ratios suggest that Broach Lifecare is trading at a discount compared to its peers, particularly when considering that Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is categorized as very expensive with a PE of 93.83.\n\nIn comparison to its industry peers, Broach Lifecare stands out as a more attractive investment opportunity, especially given its PEG ratio of 0.00, which indicates no growth premium is being paid for its earnings. Despite recent stock performance showing a decline of 25.38% over the past year compared to a slight increase in the Sensex, the un..."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3541106",
        "imagepath": "",
        "date": "2025-09-20 08:07:52",
        "description": "As of 19 September 2025, Broach Lifecare's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, especially when considering its PE ratio of 10.93 and an EV to EBITDA ratio of 11.78, which are considerably lower than its peers. For instance, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even more expensive with a PE of 93.83.\n\nBroach Lifecare's ROCE stands at 6.90% and ROE at 5.81%, suggesting solid operational efficiency relative to its peers. The PEG ratio of 0.00 further emphasizes its undervaluation, as it indicates that the stock price does not reflect the company's earnings growth potential. Despite recent stock performance lagging behind the Sensex, with a 1-year return of -25.38% compared to the Sensex's -0.67%, the underlying valuati..."
      },
      {
        "title": "Is Broach Lifecare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-broach-lifecare-overvalued-or-undervalued-3535397",
        "imagepath": "",
        "date": "2025-09-19 08:07:00",
        "description": "As of 18 September 2025, Broach Lifecare's valuation grade has moved from risky to attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 12.75, an EV to EBIT of 13.60, and a ROCE of 6.90%. In comparison to its peers, Apollo Hospitals, which has a PE ratio of 71.62, and Max Healthcare, with a PE of 94.6, Broach Lifecare presents a much more favorable valuation.\n\nDespite the attractive valuation, Broach Lifecare has experienced a decline in stock performance, with a 1-year return of -27.36%, contrasting sharply with the Sensex's modest gain of 0.08% over the same period. This discrepancy further supports the conclusion that the company is undervalued relative to its peers and market conditions...."
      }
    ],
    "total": 21,
    "sid": "10039354",
    "stock_news_url": "https://www.marketsmojo.com/news/broach-lifecare-hospital-10039354"
  },
  "announcements": [
    {
      "caption": "Unaudited Standalone Financial Results For The Half Year Ended September 30 2025 Along With The Limited Review Report.",
      "datetime": "14-Nov-2025",
      "details": "Unaudited Standalone Financial Results for the half year ended on September 30 2025 along with Limited Review Report.",
      "source": "BSE"
    },
    {
      "caption": "Intimation For Appointment Of Secretarial Auditor For The FY 2025-26",
      "datetime": "14-Nov-2025",
      "details": "M/s. N R Shah & Co Company Secretaries Vadodara was appointed as Secretarial Auditor of the company for FY 2025-06 in pursuance of section 204 of the Companies Act 2013.",
      "source": "BSE"
    },
    {
      "caption": "Statement Of Deviation(S) Or Variation(S) Of Funds Raised Through Public Issue",
      "datetime": "14-Nov-2025",
      "details": "Statement of Deviation or Variation of funds raised through public issue for the period ended on September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Broach Lifecare?

2025-11-15 00:35:57

Answer: The historical performance of Broach Lifecare shows a mixed trend in financial metrics from March 2024 to March 2025. Breakdown: In the fiscal year ending March 2025, Broach Lifecare reported net sales of 3.18 Cr, an increase from 2.61 Cr in the previous year. Total operating income also rose to 3.18 Cr from 2.61 Cr, while total expenditure increased to 2.35 Cr from 1.58 Cr. Operating profit (PBDIT) decreased to 0.88 Cr from 1.03 Cr, leading to a decline in profit before tax to 0.72 Cr from 0.93 Cr. Consequently, profit after tax fell to 0.54 Cr from 0.70 Cr. The earnings per share (EPS) dropped to 0.89 from 1.57, reflecting a decrease in profitability. On the balance sheet, shareholder's funds grew to 9.36 Cr from 5.47 Cr, and total liabilities increased to 10.92 Cr from 5.72 Cr. The company reported a cash flow from financing activities of 4.00 Cr, consistent with the previous year, while cash fl...

Is Broach Lifecare overvalued or undervalued?

2025-11-07 08:14:28

As of 6 November 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as fairly valued. Key ratios include a PE Ratio of 20.23, an EV to EBITDA of 11.78, and a ROCE of 6.90%. In comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than that of Apollo Hospitals, which stands at 71.27, highlighting a substantial valuation gap. Additionally, while Broach Lifecare's PEG Ratio is at 0.00, indicating no growth expectations, other peers like Max Healthcare and Fortis Health are considered very expensive with PEG Ratios of 6.38 and 1.88, respectively. Despite a recent stock return of 3.75% over the past week, Broach Lifecare has underperformed the Sensex over the longer term, with a year-to-date decline of 16.67% compared to the Sensex's gain of 6.62%....

Is Broach Lifecare overvalued or undervalued?

2025-10-09 08:07:08

As of 8 October 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive. Based on the analysis, the company appears to be undervalued. Key ratios include a PE Ratio of 10.35, an EV to EBIT of 11.20, and a ROCE of 6.90%. In comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than Apollo Hospitals at 70.05 and Max Healthcare at 92.31, both of which are categorized as very expensive. The PEG Ratio for Broach Lifecare stands at 0.00, indicating potential growth at a low price, further supporting the undervaluation thesis. Additionally, Broach Lifecare's recent stock performance has lagged behind the Sensex, with a year-to-date return of -21.06% compared to the Sensex's 4.65%, reinforcing the notion that the stock may be undervalued in the current market environment....

Is Broach Lifecare overvalued or undervalued?

2025-09-23 08:06:53

As of 22 September 2025, Broach Lifecare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.84, an EV to EBITDA ratio of 12.69, and a Price to Book Value of 1.27. These ratios suggest that the company is trading at a reasonable valuation compared to its earnings and book value. In comparison to its peers, Broach Lifecare's PE ratio is significantly lower than that of Max Healthcare, which is considered very expensive at a PE of 94.6, and also lower than Apollo Hospitals, which has a PE of 70.79 but is rated attractive. This positions Broach Lifecare favorably within the industry, especially given its lower PEG ratio of 0.00, indicating potential for growth at a reasonable price. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -9.72% compar...

Is Broach Lifecare overvalued or undervalued?

2025-09-22 08:08:08

As of 19 September 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive. The company is currently assessed as undervalued. Key ratios include a PE ratio of 10.93, an EV to EBITDA ratio of 11.78, and a Price to Book Value of 1.18, which indicate a favorable valuation compared to its peers. In comparison to notable competitors, Apollo Hospitals has a significantly higher PE ratio of 71.29 and an EV to EBITDA of 36.650, while Max Healthcare is even more expensive with a PE of 93.83 and an EV to EBITDA of 58.130. This stark contrast highlights Broach Lifecare's relative undervaluation in the market. Additionally, the company's recent stock performance has lagged behind the Sensex, with a one-year return of -25.38% compared to the Sensex's -0.67%, reinforcing the notion that it may be undervalued....

Is Broach Lifecare overvalued or undervalued?

2025-09-21 08:07:09

As of 19 September 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently undervalued, with a PE ratio of 10.93, an EV to EBITDA ratio of 11.78, and a Price to Book Value of 1.18. These ratios suggest that Broach Lifecare is trading at a discount compared to its peers, particularly when considering that Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is categorized as very expensive with a PE of 93.83. In comparison to its industry peers, Broach Lifecare stands out as a more attractive investment opportunity, especially given its PEG ratio of 0.00, which indicates no growth premium is being paid for its earnings. Despite recent stock performance showing a decline of 25.38% over the past year compared to a slight increase in the Sensex, the un...

Is Broach Lifecare overvalued or undervalued?

2025-09-20 08:07:52

As of 19 September 2025, Broach Lifecare's valuation grade has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, especially when considering its PE ratio of 10.93 and an EV to EBITDA ratio of 11.78, which are considerably lower than its peers. For instance, Apollo Hospitals has a PE ratio of 71.29 and an EV to EBITDA of 36.65, while Max Healthcare is even more expensive with a PE of 93.83. Broach Lifecare's ROCE stands at 6.90% and ROE at 5.81%, suggesting solid operational efficiency relative to its peers. The PEG ratio of 0.00 further emphasizes its undervaluation, as it indicates that the stock price does not reflect the company's earnings growth potential. Despite recent stock performance lagging behind the Sensex, with a 1-year return of -25.38% compared to the Sensex's -0.67%, the underlying valuati...

Is Broach Lifecare overvalued or undervalued?

2025-09-19 08:07:00

As of 18 September 2025, Broach Lifecare's valuation grade has moved from risky to attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 12.75, an EV to EBIT of 13.60, and a ROCE of 6.90%. In comparison to its peers, Apollo Hospitals, which has a PE ratio of 71.62, and Max Healthcare, with a PE of 94.6, Broach Lifecare presents a much more favorable valuation. Despite the attractive valuation, Broach Lifecare has experienced a decline in stock performance, with a 1-year return of -27.36%, contrasting sharply with the Sensex's modest gain of 0.08% over the same period. This discrepancy further supports the conclusion that the company is undervalued relative to its peers and market conditions....

View All News